Bionoid Pharma, Inc. Acquires AI Maverick Intel
Bionoid Pharma (OTC PINK:BINP) has signed a definitive agreement with Stronghold Media Group Corp. to acquire the intellectual property rights of AI Maverick Intel, a revolutionary technology for automated customer acquisition. This AI-powered platform enables companies to efficiently find, engage, nurture, and acquire ideal audiences with minimal human involvement.
As part of its strategic shift towards AI-driven execution, Bionoid has also divested its 100% stake in Medical Magnetics Inc. to Lily Zablotsky for nominal consideration. This move aligns with the company's focus on streamlining operations and leveraging AI for future growth.
Wayne Cockburn, Interim CEO of Bionoid Pharma, expressed excitement about the acquisition, stating it will redefine audience engagement and establish Bionoid as a leader in AI-driven execution.
Bionoid Pharma (OTC PINK:BINP) ha firmato un accordo definitivo con Stronghold Media Group Corp. per acquisire i diritti di proprietà intellettuale di AI Maverick Intel, una tecnologia rivoluzionaria per l'acquisizione automatizzata dei clienti. Questa piattaforma alimentata dall'IA consente alle aziende di trovare, coinvolgere, coltivare e acquisire in modo efficiente il pubblico ideale con il minimo coinvolgimento umano.
Come parte della sua transizione strategica verso l'esecuzione basata sull'IA, Bionoid ha anche ceduto la sua partecipazione del 100% in Medical Magnetics Inc. a Lily Zablotsky per un corrispettivo nominale. Questa mossa è in linea con l'obiettivo dell'azienda di semplificare le operazioni e sfruttare l'IA per una crescita futura.
Wayne Cockburn, CEO ad interim di Bionoid Pharma, ha espresso entusiasmo per l'acquisizione, affermando che ridefinirà il coinvolgimento del pubblico e stabilirà Bionoid come leader nell'esecuzione guidata dall'IA.
Bionoid Pharma (OTC PINK:BINP) ha firmado un acuerdo definitivo con Stronghold Media Group Corp. para adquirir los derechos de propiedad intelectual de AI Maverick Intel, una tecnología revolucionaria para la adquisición automatizada de clientes. Esta plataforma impulsada por IA permite a las empresas encontrar, involucrar, nutrir y adquirir audiencias ideales de manera eficiente con la mínima intervención humana.
Como parte de su cambio estratégico hacia una ejecución impulsada por IA, Bionoid también ha vendido su participación del 100% en Medical Magnetics Inc. a Lily Zablotsky por una consideración nominal. Este movimiento está alineado con el enfoque de la empresa en optimizar las operaciones y aprovechar la IA para el crecimiento futuro.
Wayne Cockburn, CEO interino de Bionoid Pharma, expresó su entusiasmo por la adquisición, afirmando que redefinirá el compromiso de la audiencia y establecerá a Bionoid como líder en la ejecución impulsada por IA.
Bionoid Pharma (OTC PINK:BINP)는 Stronghold Media Group Corp.와 지적 재산권을 인수하기 위한 최종 계약을 체결했습니다. AI Maverick Intel은 자동화된 고객 획득을 위한 혁신적인 기술입니다. 이 AI 기반 플랫폼은 기업이 최소한의 인간 개입으로 이상적인 대상을 효율적으로 찾고, 참여시키고, 육성하고, 인수하도록 돕습니다.
Bionoid는 AI 기반 실행으로의 전략적 전환의 일환으로 Medical Magnetics Inc.의 100% 지분을 Lily Zablotsky에게 최소한의 대가로 매각했습니다. 이 조치는 회사의 운영을 간소화하고 미래 성장을 위한 AI 활용에 초점을 맞추고 있습니다.
Bionoid Pharma의 임시 CEO인 Wayne Cockburn는 인수에 대한 기대감을 표명하며, 이는 청중 참여를 재정의하고 Bionoid를 AI 기반 실행의 선두주자로 자리매김하게 할 것이라고 말했습니다.
Bionoid Pharma (OTC PINK:BINP) a signé un accord définitif avec Stronghold Media Group Corp. pour acquérir les droits de propriété intellectuelle de AI Maverick Intel, une technologie révolutionnaire pour l'acquisition automatisée de clients. Cette plateforme alimentée par l'IA permet aux entreprises de trouver, d'engager, de nourrir et d'acquérir efficacement des audiences idéales avec un minimum d'implication humaine.
Dans le cadre de son changement stratégique vers une exécution pilotée par l'IA, Bionoid a également cédé sa participation de 100 % dans Medical Magnetics Inc. à Lily Zablotsky pour une contrepartie nominale. Ce mouvement est en accord avec l'objectif de l'entreprise de rationaliser ses opérations et d'exploiter l'IA pour une croissance future.
Wayne Cockburn, CEO par intérim de Bionoid Pharma, a exprimé son enthousiasme pour cette acquisition, affirmant qu'elle redéfinira l'engagement du public et établira Bionoid comme un leader dans l'exécution pilotée par l'IA.
Bionoid Pharma (OTC PINK:BINP) hat einen endgültigen Vertrag mit Stronghold Media Group Corp. unterzeichnet, um die geistigen Eigentumsrechte von AI Maverick Intel zu erwerben, einer revolutionären Technologie zur automatisierten Kundenakquise. Diese KI-gesteuerte Plattform ermöglicht es Unternehmen, ideale Zielgruppen effizient zu finden, zu engagieren, zu pflegen und mit minimalem menschlichem Aufwand zu gewinnen.
Im Rahmen seiner strategischen Neuausrichtung auf KI-gesteuerte Ausführung hat Bionoid auch seine 100%ige Beteiligung an Medical Magnetics Inc. an Lily Zablotsky zu einem nominellen Preis verkauft. Dieser Schritt steht im Einklang mit dem Fokus des Unternehmens auf die Optimierung von Abläufen und die Nutzung von KI für zukünftiges Wachstum.
Wayne Cockburn, Interim-CEO von Bionoid Pharma, äußerte sich begeistert über die Akquisition und erklärte, dass sie das Publikum-Engagement neu definieren und Bionoid als führenden Anbieter im Bereich der KI-gesteuerten Ausführung etablieren wird.
- Acquisition of AI Maverick Intel's intellectual property rights
- Potential for improved customer acquisition efficiency and productivity
- Strategic shift towards AI-driven execution and innovation
- Streamlining of operations through divestiture of Medical Magnetics Inc.
- Divestiture of Medical Magnetics Inc. for nominal consideration may result in loss of potential revenue stream
- Potential integration challenges and costs associated with implementing new AI technology
"Pioneering Fully Automated AI Customer Acquisition"
TORONTO, ON / ACCESSWIRE / August 8, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) announces the signing of a definitive agreement with Stronghold Media Group Corp. ("Stronghold") to acquire the intellectual property rights of AI Maverick Intel, a cutting-edge technology set to revolutionize customer acquisition by enabling companies to find, engage, nurture, and acquire their ideal audiences at high velocity and automated scale.
Revolutionizing Audience Engagement with AI Maverick Intel
AI Maverick Intel is a game-changer in tech acquisitions. Utilizing state-of-the-art AI technology, it redefines how companies identify, reach, and engage their target audiences. The platform's advanced automation capabilities empower businesses to achieve efficient customer acquisition with minimal human involvement, maximizing productivity and precision at every touchpoint.
"We are very excited about this new chapter for Bionoid Pharma," said Wayne Cockburn, Interim CEO of Bionoid Pharma. "By harnessing the transformative power of AI Maverick Intel, we are poised to redefine audience engagement. This acquisition propels us towards a future where companies can seamlessly acquire customers with less data and communication fragmentation. It underscores our unwavering commitment to innovation, sustainable growth, and establishing Bionoid as a leader in AI-driven execution."
A Strategic Divestiture to Focus on Digital Transformation
In alignment with this new strategic direction, Bionoid Pharma has sold its
About AI Maverick Intel
AI Maverick Intel is at the forefront of digital transformation in audience engagement. By leveraging cutting-edge AI and machine learning algorithms, this platform redefines how companies connect and scale communications with their target audiences. Its sophisticated automation capabilities ensure highly efficient and impactful marketing campaigns, driving seamless and automated customer acquisition.
For further information, contact:
Wayne Cockburn, Interim CEO
Phone: (905) 505-0770
bionoidpharma@gmail.com
SOURCE: Bionoid Pharma, Inc.
View the original press release on accesswire.com
FAQ
What is the purpose of Bionoid Pharma's acquisition of AI Maverick Intel?
How will the AI Maverick Intel acquisition impact Bionoid Pharma's (BINP) business strategy?
What did Bionoid Pharma (BINP) divest as part of its new strategic direction?
When did Bionoid Pharma (BINP) announce the acquisition of AI Maverick Intel?
